RECRUITING

GLP-1R Agonist Treatment for Opioid Use Disorder

Conditions

Opioid Use Disorder Opioid Abuse and Addiction Narcotic-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorder Opioid Opiate treatment Opioid treatment Glucagon-Like Peptide-1 Agonist Semaglutide

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids. The participants will: * Take semaglutide or a placebo every week for 12 weeks * Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires * Complete smartphone surveys sent at set times during the study

Official Title

GLP-1R Agonist Treatment for Opioid Use Disorder

Quick Facts

Study Start:2025-01-13

Study Completion:2026-11

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06548490

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age 18 to 75 years. * Body mass index (BMI) \> 18. * Able and willing to provide informed consent prior to any study-related activities. * Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \> 3. * Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and/or at an associated clinic at the time of enrollment. * Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone. * Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone. * If anatomically capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study. * Able to read and communicate in English to the level required to accept standard care and complete all study requirements. * Able and willing to engage/adhere to the entirety of the study protocol (19 weeks). * Not currently a prisoner.	* Age \< 18 or \> 75 years. * BMI \<18. * Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures. * Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist. * History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist. * Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule. * Type 1 diabetes or history of diabetic ketoacidosis. * Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor. * Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide. * Hypoglycemia on intake visit (blood glucose \< 60 mg/dL). * End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \<30 mL/min per 1.73 square meters or previous renal transplant. * End stage liver disease or previous liver transplant. * Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease. * Current or past diagnosis of gallbladder disease or gallstones. * Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke). * Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and/or history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and/or physician. As there is no specific scale that determines this, this will include the Site PI/physician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location. * Significant risk of suicide requiring a different/higher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and/or judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide. * Treatment with any investigational drug in the one month preceding the study. * Any contraindication to methadone, BUP, or a GLP-1R agonist. * Previous randomization for participation in this trial. * Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician. * Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study. * Currently a prisoner.

Inclusion Criteria

Exclusion Criteria

* Age 18 to 75 years.
* Body mass index (BMI) \> 18.
* Able and willing to provide informed consent prior to any study-related activities.
* Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \> 3.
* Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and/or at an associated clinic at the time of enrollment.
* Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone.
* Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone.
* If anatomically capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study.
* Able to read and communicate in English to the level required to accept standard care and complete all study requirements.
* Able and willing to engage/adhere to the entirety of the study protocol (19 weeks).
* Not currently a prisoner.

* Age \< 18 or \> 75 years.
* BMI \<18.
* Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.
* Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.
* History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.
* Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule.
* Type 1 diabetes or history of diabetic ketoacidosis.
* Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor.
* Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide.
* Hypoglycemia on intake visit (blood glucose \< 60 mg/dL).
* End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \<30 mL/min per 1.73 square meters or previous renal transplant.
* End stage liver disease or previous liver transplant.
* Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease.
* Current or past diagnosis of gallbladder disease or gallstones.
* Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke).
* Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and/or history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and/or physician. As there is no specific scale that determines this, this will include the Site PI/physician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location.
* Significant risk of suicide requiring a different/higher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and/or judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide.
* Treatment with any investigational drug in the one month preceding the study.
* Any contraindication to methadone, BUP, or a GLP-1R agonist.
* Previous randomization for participation in this trial.
* Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician.
* Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study.
* Currently a prisoner.

Contacts and Locations

Study Contact

Jennifer Nyland, PhD

CONTACT

717-531-6172

jnyland@pennstatehealth.psu.edu

Kirsten Shuler, MSc

CONTACT

717-531-4104

kshuler@pennstatehealth.psu.edu

Principal Investigator

Jennifer Nyland, PhD

PRINCIPAL_INVESTIGATOR

Milton S. Hershey Medical Center

Study Locations (Sites)

Pennsylvania Psychiatric Institute

Harrisburg, Pennsylvania, 17110

United States

Collaborators and Investigators

Sponsor: Milton S. Hershey Medical Center

Jennifer Nyland, PhD, PRINCIPAL_INVESTIGATOR, Milton S. Hershey Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-13

Study Completion Date2026-11

Study Record Updates

Study Start Date2025-01-13

Study Completion Date2026-11

Terms related to this study

Keywords Provided by Researchers

Opiate treatment
Opioid treatment
Glucagon-Like Peptide-1 Agonist
Opioid use disorder
Semaglutide

Additional Relevant MeSH Terms

Opioid Use Disorder
Opioid Abuse and Addiction
Narcotic-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorder
Opioid